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SUMMARY 
In Schistosoma mansoni endemic areas, there are people with ongoing S. mansoni 
infection, others have been infected and treated while others have never been 
infected. What would happen if these different groups of people were vaccinated 
against S. mansoni? BALB/c mice were divided into five groups: Infected-Treated-
Vaccinated; Infected-Vaccinated-Treated; Vaccinated-Treated Control; Challenge 
Control and Untreated challenge Control. Vaccination (500 20krad irradiated S. 
mansoni cercariae), Treatment (praziquantel), Infection and Challenge (150 S. 
mansoni cercariae) were carried out at specified times. Proliferation assay, Enzyme 
linked immunosorbent assay, gross pathology, histopathology and perfusion were 
performed. High protection levels were obtained in mice treated after vaccination: 
Vaccinated-Treated control, 96.5%; Infected-Vaccinated-Treated, 68.9%; and 
Infected-Treated-Vaccinated, 41%. A good correlation was obtained between 
proliferative responses and protective levels, implying cellular involvement in 
protection. Although all protected animals had high IgG levels, there was no strong 
correlation between the two. Specificity rather than amounts of IgG, seem more 
important in protection. Praziquantel seemed to boost protective immunity when 
administered after vaccination. Granuloma development and modulation in the two 
test groups was similar. It seems better to vaccinate infected patients before 
treatment, the ideal situation being vaccinating people who have not encountered S. 
mansoni.  
[Afr J Health Sci. 2006; 13:55-68] 
*Published online before print 
 
Introduction 
Schistosomiasis causes a chronic debilitating 
disease especially among the youth and children 
[1]. The global prevalence of the disease has 
remained approximately 200 million for decades 
[2], even in the presence of a safe and 
efficacious therapeutic drugs. Although 
chemotherapy remains the cornerstone of 
intervention, there is need for a more long-term 
approach, since the rapid re-infection demands 




to drug resistance [3,4]. Therefore it seems that 
the potential control of this disease will rely on 
multiple and integrated strategies, among which  
the modern tools of immunointerventions will 
play a major role. Based mainly on the murine 
challenge models, a number of candidate 
antigens have been proposed following 
immunizations with either irradiated cercariae or 
purified sub units [5,6]. These antigens usually 
demonstrate immunoreactivity with sera and 
peripheral blood mononuclear cells from 
infected patients [7]. Such studies have provided 
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the justification for initiating vaccine 
development, with the aim of testing one or 
more candidate antigens in phase 1 clinical trials 
[8,5]. However, it is of paramount importance to 
evaluate any potential risk that may result during 
field clinical trials of a schistosomiasis vaccine. 
The reason being that in endemic areas, it is 
probable that there will be individuals who have 
undetected infections while others may have 
been infected and treated. The goal of the 
present study was to elucidate the effect of 20 
krad radiation-attenuated vaccine when 
administered either before or after praziquantel 
treatment in S. mansoni infected BALB/c mice. 
Radiation-attenuated vaccine has given good 
protection levels in both murine and primate 
models [9-11]. Although the vaccine cannot be 
used in humans due to ethical reasons, it is 
useful in studying the immunological, 
parasitological and pathological responses of a 
working vaccine. 
 
Materials and Methods 
Experimental design 
In this study, BALB/c mice were placed into 
five groups: Infected-Treated-Vaccinated (ITV), 
Infected-Vaccinated-Treated (IVT), Vaccinated-
Treated Control (VC), Challenge Control (CC) 
and Untreated Challenge Control (UTCC). Mice 
in ITV were infected, treated with praziquantel, 
vaccinated and challenged. Mice in IVT were 
infected, vaccinated, treated with praziquantel 
and then challenged. VC mice were vaccinated, 
treated with praziquantel and then challenged. 
CC mice were treated with praziquantel 4 days 
before challenge infection. UTCC mice were 
infected with normal cercariae and not treated at 
all. Five mice were sampled per every sampling 
point. A schematic representation of the 
experimental design is given in Fig. 1
 
Fig. 1 Experimental Design 
 
Weeks  0    5       6      9   11   12     14    16    17 
 
ITV       I   T/S    V/S    S         CH      S       S       P 
 
IVT      I           V       S   T      CH    S      S       P 
 
VC                  V       S    T     CH     S        S       P 
 
CC                            S    T     CH    S        S      P 
 
UTCC                                 CH                   P 
 
KEY: ITV, Infected-Treated-Vaccinated group; IVT, Infected-Vaccinated-Treated; VC, 
Vaccinated-Treated Control group; CC, Challenge control group; UTCC, Untreated Challenge 
Control Group. 




BALB/c mice, 8 weeks old (at the 
commencement of the experiment) were used in 
this study. They were bred at the Animal 
Resource Department of the Institute of Primate 
Research (IPR), Kenya. Mice were fed with 
nutrient pellets from Unga Feeds® Co., Kenya, 
and water supplied ad libitum. 
 
Parasite and Intermediate Host 
Schistosoma mansoni eggs were obtained from 
faecal material of infected olive baboons that 
were maintained at the Institute of Primate 
Research, IPR, Kenya. The eggs were hatched 
and 5-8 miracidia were used to infect each fresh 
water snails, Biomphalaria pfeifferi. The snails 
were maintained at the Snail Facility at IPR, 
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Kenya. 
 
Preparation of the vaccine 
Normal cercariae were quantified and then 
irradiated by 20 krad emmited from caesium-
137 gamma source at the International Livestock 
Research Institute (ILRI), Kenya.  
 
Infection, Challenge and Vaccination 
Infected snails were shed and cercariae 
quantified for infection, challenge and for 
preparing radiation-attenuated vaccine at 
specified times. During infection, challenge and 
vaccination, mice were anaesthetized with a 
mixture of Rompun and Ketamine (Agrar, 
Holland) at 0.02ml/30g body weight via 
intraperitoneum. Mice for infection and 
challenge received 150 normal S. mansoni 
cercariae, while those for vaccination received 
500 20 krad radiation-attenuated parasites each. 
Mouse abdomen was shaved and a metal ring 
1cm in diameter was placed on the wet shaved 
area. Parasite suspension was placed in the metal 




Praziquantel (Biltricide®, Bayer, Germany) 
tablets were ground into powder and then 
dissolved in distilled water. A dose of 
450mg/kg/body weight was given orally to each 
mouse [12]. Two doses of the drug were given 
48 h apart. 
 
Preparation of Antigens  
18 hr soluble larval antigen (SSP) was prepared 
following artificial transformation of S. mansoni 
cercariae [13] and separation of heads from tails 
on a discontinuous Percoll gradient [14]. The 
schistosomules were cultured at 37oC, 5% CO2 
in Complete medium [RMPI 1640, 0.2mg/ml 
Gentamycin, 1% glutamine (2MM); 1% 2-
mercaptoethanol (5x10-5 M), fortified with 10% 
foetal calf serum] under sterile conditions for 18 
h. They were then pelleted and washed two 
times in PBS and sonicated (24 kHz, 16mm 
amplitude, 10 min) before centrifugation at 
100,000 g for 1 h to obtain the soluble fraction. 
The protein content was determined [15] and the 
solution was UV-sterilized and stored at –70oC. 
Soluble worm antigen (SWAP) was prepared 
from 5-week-old worms recovered from 
baboons [10]. A commercially prepared 
Concanavalin A (Con A; Sigma Co.) was 
dissolved in sterile PBS to make a concentration 
of 1mg/ml. The solution was sterilized by 
Nalgene disposable filter (Nalgene Co., USA). 
 
Proliferation assay 
Spleen from each mouse was placed in sterile 
wire gauze, in a petri dish containing sterile 
Incomplete medium [RMPI 1640, 0.2mg/ml 
Gentamycin, 1% glutamine (2MM); 1% 2-
mercaptoethanol (5x10-5 M)]. A 10ml syringe 
piston was used to squash the organ. The 
dispersed cells were dispensed in 15ml tubes and 
topped up with Incomplete medium. The cell 
suspension was centrifuged twice at 450 g for 10 
minutes, each time discarding the supernatant. 
The final pellet was re-suspended in 4 ml of 
Complete medium. Lymphocyte viability was 
determined by Trypan blue exclusion test. 
Lymphocytes were counted in a 
haemocytometer chamber. Cells for the culture 
were made up to 3x106 cells/ml in Complete 
medium. Lymph node cells were prepared by 
teasing the organ using sterile forceps in petri 
dish containing sterile Incomplete medium. The 
cells were prepared for culture based on the 
procedure used for spleen cells. 
        Spleen cells and lymph node cells were 
cultured in flat-bottomed 96-well microtitre 
plates (Nunclon, Denmark). Duplicate wells 
were set for each regime, each well containing 
3x105 viable cells. Negative control had the 
medium and cells only while positive control 
had 1 µg/well of Con A. The test wells of each 
plate contained 1 µg/well of soluble worm 
antigen preparation (SWAP) or 0.5 µg/well of 
18 hr soluble larval antigen preparation (SSP). 
The total volume of culture medium per well 
was made up to 200 µl. The plates were 
incubated at 37oC, in the presence of 5% carbon 
dioxide. After either 48 h or 72 h for Con A and 
for other set-ups, respectively, the cells were 
pulsed with 20 µl of 18.5 MBq tritiated 
thymidine (3H-thymidine; Amersham 
Pharmacia, UK). After 18 h, the cells were 
harvested on microfibre filter using Filtermate 
Harvester (Packard Bioscience Co. USA). The 




58               African Journal of Health Sciences, Volume 13, Number 1-2, January-June 2006             
scintillation counting. Results were expressed as 
differential counts, ∆ CPM, that is CPM of Con 
A or antigen-stimulated cultures – CPM of 




The SWAP-specific ELISA was performed by 
coating Immunolon 4 plates (Dynatech, USA) 
with 10 µg/ml of SWAP in carbonate 
bicarbonate buffer (pH of 9.6) overnight at 4oC. 
Plates were subsequently blocked with PBS plus 
0.05% Tween 20 (Fisher Chemicals, USA) and 
3% BSA for I h at 37oC. After washing, a 1:4 
dilution of mice sera was added and incubated at 
37oC for 2 h. Plates were washed again and goat 
anti-mouse IgG conjugated to horse-radish 
peroxidase was added and incubated for 1 h at 
37oC. Plates were washed again, substrate (TMB 
micro well peroxidase substrate, Kirkegaard & 
Perry Labs, USA) was added, and optical 
density (OD) determined at 630 nm. 
 
Perfusion and worm recovery  
Based on the modified method of Smithers and 
Terry [16], mice were anaesthetised and hepatic 
portal vein incised. Perfusion needle containing 
perfusion fluid (0.85% Sodium chloride and 
1.5% Sodium citrate) was inserted on the left 
ventricle of the heart and perfusion carried out 
until the liver, lower limbs and mesenteries were 
clear. The perfusate was collected in plastic 
container and transferred in a urine jar to settle. 
The supernatant was sucked out and worms 
recovered [10]. The mean and percentage worm 
reduction of adult worms recovered for each 
group was calculated. Worm maturation was 
also calculated for the control groups.  
 
Gross pathology and histopathology  
Gross pathology of the liver and the mesenteric 
lymph nodes was observed.  The observations 
considered in the liver included the colour, size 
and presence of granulomas. Representative 
biopsy samples of the liver were fixed 
immediately in 10% buffered formalin for at 
least two weeks. The tissues were cleared in 
toluene, infiltrated in hot paraffin and embedded 
on tissue-embedding paraffin wax (Sherwood 
Medical Co. USA). The tissues were sectioned 
serially at 6 microtomes using a Rotary 
microtome (Leitz, Germany). The thin tissue 
sections were mounted on glass slides and 
stained with haematoxylin and eosin. The tissue 
sections were observed under light microscope 
and only granulomas containing an ovum in the 
centre were enumerated and measured at 100x 
magnification using calibrated ocular 
micrometer. The vertical and horizontal 
diameters of granulomas with a visible centrally 
placed schistosome egg were measured using the 
ocular micrometer [12]. The averages of the 
horizontal and vertical diameter were taken to be 
the diameter of the granulomas. Ten granulomas 
were measured for each mouse. 
 
Statistical analysis 
Analysis of variance (ANOVA), Kruskal Wallis 
test and the Student's t-test, were used in data 




Lymphocyte Proliferative responses 
Proliferative Responses to SSP: 
Lymph node (LN) cells responses to SSP are 
shown in Fig. 2 (i) and (ii). The three vaccinated 
groups: Infected-Treated-Vaccinated (ITV), 
Infected-Vaccinated-Treated (IVT) and 
Vaccinated-Treated Control (VC) groups had 
similar responses to SSP. They had either low or 
background responses 3 weeks post-vaccination 
(wk pv). The responses were boosted by 
challenge infection as demonstrated by a peak 2 
weeks post-challenge (wk pc). However, at 4 wk 
pc, the responses were either low or at 
background levels. The Challenge Control (CC) 
had substantial response 2 wk pc, but the level 
had gone down by 4 wk pc.  
         Spleen Cells responses to SSP are shown 
in Fig. 2 (iii) and (iv). Although the trend for 
spleen cells responses for mice IVT and the VC 
was similar, the responses for the former group 
were much lower (Fig 2.iv). The two groups had 
noticeable responses 3 wk pv, a peak at 2 wk pc 
and a decline 4 wk pc. Spleen cells of ITV had 
remarkable response at 3 wk pv, which declined 
slightly 2 wk pc and remained almost at the 
same level at week 4 wk pc (Fig. 2.iii). CC had  
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high response at 2 wk pc. The responses were still going up by 4 wk pc. 
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Proliferative responses to SWAP: 
Lymph node cells responses to SWAP are 
shown in Fig. 3 (i) and (ii). LN cells of IVT and 
the VC demonstrated similar responses to 
SWAP, although VC had higher response (Fig. 
3.iii). Both had low responses at 3 wk pv. They 
attained a peak at 2 wk pc with the peak being 
higher for VC. Unlike the VC, IVT had a 
background response by 4 wk pc. ITV had high 
responses at 5 wk post-infection (pi; Fig. 3.i). 
The first peak was observed 1 wk after 
treatment, at the time when large amounts of 
antigen were being released from the dying 
worms. However, at 3 wk pv, no response was 
observed. Two weeks after challenge, there was 
a remarkable response, which was only slightly 
decreased 4 wk pc. The Challenge Control group 
had a response recorded only at wk 4 wk pc at 
the time when worms start maturing. Spleen 
cells responses to SWAP are shown in Fig. 3 
(iii) and (iv). Spleen cells of IVT and VC had 
similar responses, with a remarkable response at 
Fig. 2: Proliferative responses of Lymph node cells (i & ii) and Spleen cells (iii & iv) to  
18 h soluble  antigen preparation SSP (i & iii = ITV & controls; ii & iv = IVT & controls)
ITV: Infected-Treated- Vaccinated group; IVT: Infected-Vaccinated-Treated group; VC: Vaccinated-Treated 
Control; CC: Challenge control group. 
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Spleen cells of ITV had reasonable responses at 
5 wk pi and a peak was obtained 1 wk after 
treatment.  The response had decreased by 3 wk 
pv, and was lower 2 wk pc, though it remained 
remarkable. The response remained more-or-less 
at the same level by 4 wk pc. The challenge 
control animals had a high response by 2 wk pc, 
and by 4 wk pc, a slight elevation was 
noticeable. 
  
 IgG antibody responses 
SWAP-specific IgG responses of the four groups 
of mice are shown in Fig. 4. IVT had a steady 
increase of IgG from infection up to a peak at 2 
wk pc, followed by a drop at 4 wk pc. VC had a 
Fig. 3: Proliferative responses of Lymph node cells (i & ii)and Spleen cells (iii & iv) to soluble worm 
antigen preparation (SWAP)  (i & iii = ITV & controls; ii & iv = IVT & controls) 
ITV: Infected-Treated-Vaccinated group; IVT: Infected-Vaccinated-Treated group; VC: Vaccinated-
Treated control group; CC: Challenge control group 
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similar trend as IVT from 3 wk pv up to 4 wk 
pc. However, IVT had consistently higher 
responses as compared to VC throughout the 
sampling period. ITV had an initial peak 6 wk 
pi, a week after treatment with praziquantel. 
This was followed by a drop at 7 wk pi. 
However, by 3 wk pv, the levels had started 
rising and a peak was attained 2 wk pc. By 4 wk 
pc, a drop in IgG level was registered. The trend 
between 3 wk pv and 4 wk pc for ITV was 
similar to VC. CC had noticeable response 2 wk 
pc and this was still going up by 4 wk pc.  
 
Warm Maturation 
Worm maturation from Challenge Control (CC) 
and Untreated Challenge Control (UTCC) was 
calculated as shown below; 
 
Worm maturation = Number of worms recovered  X  100% 
                                Initial number of infecting parasites 
 
CC, which had received treatment prior 
infection, had a mean burden of 17 worms and 
worm maturation of 11.3%. UTCC, which was 
just infected without being treated, had a mean  
Burden of 29 worms and worm maturation of 
19.3% 
 
Fig. 4: SWAP-specific IgG levels 
     
 
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
 
Worm resistance 
When worm burdens for the vaccinated groups 
were subjected to ANOVA, there was a 
significant difference (F 4,16 = 11.307, P = 
0.000) between the groups vaccinated before 
treatment (IVT and VC) and the group treated 
before vaccination (ITV). The above results 
were confirmed by the Kruskal Wallis test (X2 = 
16.664, P = 0.002), Post hoc (Turkey) analysis. 
The mean difference was significant at the 0.05 
level. There was no significant difference 
between IVT and VC. Worm resistance for ITV, 
IVT and VC was calculated using the formula 
shown below. 
 
Worm Resistance = (Challenge control worms - 
Experimental group worms) x 100 
Challenge control worms  
        The highest worm resistance was attained 
by VC, 96.5% followed by IVT with 68.9% and 
finally ITV with 41%. 
 
Gross pathology  
 At 9 wk pi (3 wk pv), the surfaces of the liver 
lobes from ITV and IVT were covered entirely 
by whitish /creamy spots (granulomas). The 
usually smooth liver surface was replaced with 
rugged surface. Moreover, the liver appeared 
pale as opposed to the red-pink hue in normal 
livers. The organ was enlarged and edematous. 
At 14 wk pi (2 wk pc) the liver in these two 
groups showed no gross pathological differences 
from the ones observed at 9 wk pi (3 wk pv), 
except that the livers had become dark in 
appearance. At 16 wk pi (4 wk pc), livers from 
mice in group ITV and IVT were darker than 
previously noticed. Granulomatous spots were 
numerous and covered every part of the liver 
lobes.  
         The Granulomas appeared to be protruding 
slightly above the liver capsule. The livers were 
gritty to touch and creamy patches were also 
observed at the edges of the liver lobes in some 
mice. The liver was prominently enlarged. At 17 
wk pi (5 wk pc), gross pathology of the liver of 
these two groups showed no marked difference 
from the observations made at week 16 wk pi (4 
wk pc).  
       Throughout the sampling period, livers from 
the VC and CC, had the texture, size and colour 
of normal liver. There were no observable 
ITV: Infected-Treated- Vaccinated 
IVT: Infected-Vaccinated-Treated 
VC: Vaccinated -Treated control 
CC: Challenge control 
 
 I = infected; T = treatment of ITV;  T2 = treatment for 
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changes. The livers lacked visible granulomas 
and retained the smooth texture, sharp edges and 
pink-red hue. There was no pronounced liver 
enlargement or oedema. Enlarged mesenteric 
lymph nodes were also observed in different 
mice groups at different time points. 
Enlargement of the mesenteric lymph nodes of 
ITV was observed at 9 wk pi (3 wk pv) and the 
size remained more or less the same from 2 wk 
pc to week 5 wk pc. IVT mesenteric LN were 
enlarged at 9 wk pi (3 wk pv) and became more 
enlarged and inflamed as from 14 wk pi (2 wk 
pc) up to 17 wk pi (5 wk pc). VC mesenteric LN 
were enlarged  from 14 wk pi (2 wk pc). CC 
mesenteric lymph node showed slight 
enlargement as from 16 wk pi (4 wk pc). 
 
Histopathological  findings 
Granuloma diameters are shown in Fig. 5. Peak 
liver granuloma size was observed 9 wk pi (3 wk 
pv) in both ITV and IVT. The granulomas were 
large and florid each with a conspicuous egg at 
the centre. Hepatic granulomas from mice in 
ITV, did not show significant granuloma size 
reduction between 9 wk pi (3 wk pv) and 14 wk 
pi (2 wk pc), whereas, IVT showed some 
reduction from 9 wk pi (3 wk pv) through to 14 
wk pi (4 wk pc). At week 16 pi (4 wk pc), both 
ITV and IVT had significantly smaller 
granulomas, (P <0.05), as compared to those of  
9 wk pi (3 pv). At 17 wk pi, granuloma sizes of 
ITV and IVT had significantly increased as 
compared to 16 wk pi (P <0.05). The VC and 
CC lacked granulomas with centrally placed 
egg. However, CC had few patches of 
inflammatory foci.  
         Periportal fibrosis and periportal cellular 
infiltration were observed in some liver tissues 
from mice in both ITV and IVT. Periportal 
fibrosis surrounded the portal vein, while diffuse 
cellular infiltration were observed around the 
bile ducts. In such tissues, granulomatous foci 
were scanty or absent completely. Adult worms 
embolized on the portal veins were observed in 
the liver sections from mice in these two groups 
only. The worms were observed by week 9 pi (3 
wk pv) in ITV, while in IVT they were observed 
by 14 wk  pi (2 wk pc). Such portal veins were 
heavily surrounded with thick layer of fibrotic 
material on the inner wall, while on the outside, 
heavy cellular infiltration were very 
conspicuous. Coalescing granulomas 
surrounding two or three schistosome eggs were 
also observed in livers from the two groups.  
Intestinal granulomas were only observed in 
mice from ITV and IVT. These granulomas 
were few but diffuse in size. They were found 
mostly within the serosal surface of the intestine. 
 
Fig. 5: Granuloma sizes 
 
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     




Antigen specific lymphocyte proliferation, the 
assay commonly used for assessing cellular 
responses after immunisation, was used in this 
study. The presence of lymphocytes that have 
memory to a specific antigen are detected by 
their subsequent in vitro proliferation when re-
exposed to the same antigen. Although, this 
assay does not reveal the functional capabilities 
of the responding lymphocytes, it does indicate 
that cell are able to recognise the particular 
antigen that had activated them previously. 
Given the supposed involvement of lymphocytes 
in immune elimination of challenge 
schistosomula from vaccinated mice  [17, 18] it 
might be anticipated that successful vaccination 
ITV: Infected-Treated-Vaccinated group = 
dark bars; IVT: Infected-Vaccinated-
Treated group = open bars 
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would preferably stimulate the proliferation of T 
cells in particular draining lymph nodes. Both 
lymph node and spleen cells from the 
Vaccination-Treated Control group 
demonstrated the highest proliferative responses 
to schistosome antigens as compared to the other 
three groups. Notable responses were observed 3 
weeks after vaccination; a peak response was 
recorded 2 weeks after challenge, then a decline 
at 4 weeks post-challenge. This finding is in 
agreement with other studies in which 
proliferative responses of lymphocytes to 
schistosomal antigens were found to peak during 
the first two weeks after vaccination, waning 
after the fourth [19, 20]. The attenuated parasites 
release significant amounts of antigenic material 
during their passage through the skin, lymph 
nodes and lungs where they eventually die [19, 
20]. Responses to SWAP at week 3 post-
vaccination were substantial, a time when the 
vaccinating parasites were still at the larval 
stages. This response to SWAP could be due to 
the extensive cross reactivity between worm 
antigens and schistosomula antigens [21].  
          Proliferative responses to schistosome 
antigens of lymph node and spleen cells from 
Infected-Vaccinated-Treated mice had similar 
patterns to the Vaccination-Treated Control 
groups. However, at almost all points, the 
responses were lower than those of the 
Vaccination-Treated Control group. Treating 
this group just before challenge resulted in large 
amounts of antigens being released from the 
dead worms (infection parasites). Additional 
amount of antigen was released by the challenge 
parasites themselves. The large amount of 
antigen could have resulted in anergic responses, 
hence the lower responses recorded in this group 
as compared to the Vaccination Control group. 
Worms killed by praziquantel introduce a large 
amount of antigens directly into the blood 
stream and their persistence may cause over-
stimulation of lymphocyte clones, leading to 
suppression of proliferative response. Moreover, 
the presence of high concentration of antigens in 
circulation may favour direct interaction of 
antigens with lymphocytes without the 
participation of antigen presenting cells (APCs) 
and thus cause unresponsiveness [22]. On the 
contrary, at the time when the Vaccinated-
Treated Control mice were treated at week 5 
post-vaccination, all the vaccinating parasites 
had died [23] hence no extra amounts of antigen 
were released from the parasites in this group 
which would have resulted to an anergic effect. 
In the Infected-Treated-Vaccinated mice, 
responses of both lymph node and spleen cells to 
SWAP, before vaccination were very interesting.  
High proliferative responses were observed at 
week 5 post-infection. By week 5, worms have 
matured and started laying eggs; antigens from 
both adult worms and eggs were responsible for 
the high proliferative responses. In this group, 
mice were also treated at week 5, and by week 6 
peak responses were attained which were higher 
than any other responses observed in the entire 
sampling period. This was due the immediate 
response of antigens released from the dead 
worms. However by week 3 post-vaccination, 
the responses had gone down. This could be 
attributed to anergic effect of the large amounts 
of antigens from dead worms. Antigens released 
from vaccinating parasites most probably 
encountered unresponsive lymphocytes resulting 
into the not so dramatic response observed 3 
weeks after vaccination. This lymphocyte 
unresponsiveness seems to have remained even 
after challenge.  
          In the Challenge Control group, responses 
to the schistosome antigens were recorded at 
week 2 and 4 post-infection for both cell types, 
except for lymph node cells responses to SWAP 
which were only observed at week 4 post-




The IgG isotype, particularly IgG1, seems to be 
protective and may be synergistically enhanced 
by IgM [24]. The Infected-Vaccinated-Treated 
group had the highest IgG levels throughout the 
experiment except at week 4 post-challenge. 
Vaccination, treatment and challenge seem to 
have boosted the effect of infection, resulting to 
a steady increase of SWAP-specific IgG to a 
peak at week 2 post-challenge. The drop at week 
4 post-challenge could be attributed to lower 
antigen load as a result of few challenge 
parasites, compounded by death of challenge 
parasites as a result of vaccination [23].  
The Vaccinated-Treated Control group had a 
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Treated group from week 3 post-vaccination, 
except that the levels were much lower. As 
expected, vaccination resulted in elevated IgG 
levels that were boosted by challenge. IgG titres 
are enhanced by repeated vaccinations with 
irradiated cercariae, or after challenge infection 
with normal cercariae [25]. The levels were 
much lower as compared to the Infected-
Vaccinated-Treated group most probably 
because the Vaccinated-Treated Control group 
encountered the parasite only twice while the 
other group had more encounters with parasite 
antigen. Among the three vaccinated groups, the 
Vaccinated-Treated Control group had the 
lowest level of IgG at week 4 post-challenge, 
most probably due lower parasite numbers at 
this time as a result of parasite killing by the 
vaccine. 
           The Infected-Treated-Vaccinated group 
had high IgG levels by week 6 post-infection, 
most probably as a result of large amount of 
antigens released from the dying worms. 
However, by week 7, the levels had gone down 
because of clearance of antigens from dead 
worms from circulation. Vaccination and 
challenge increased the antigenic load in the 
circulation, and at week 3 post-vaccination and 
week 2 post-challenge, both this group and the 
challenge control group had similar IgG levels. 
On the other hand, at week 4 post-challenge, this 
group recorded the highest level of IgG among 
the three vaccinated groups. 
           The Challenge Control group SWAP-
specific IgG levels were evident at week 2 post-
infection and had gone up by week 4 post-
infection, but not as high as the other three 
groups. This could be attributed to the low 
antigenic load as a result of one infection only. 
A similar trend was reported for baboons 
infected with. S. mansoni [10]. 
 
Worm maturation and resistance 
The Challenge Control group that had been 
given oral dose of praziquantel 4 days prior to 
challenge had a lower worm maturation (11.3%) 
as compared to the Challenge Control group, 
which did not receive any treatment prior to 
challenge (19.3%). The results show that the 
drug might have sensitized the immune system 
of the treated Challenge Control against the 
penetrating parasites. Praziquantel metabolites 
may have triggered non-specific antibody 
responses and/or the presence of the 
schistosomula may have provoked antigen 
dependent cellular cytotoxicity (ADCC). The 
surface of the newly transformed schistosomula 
of S. mansoni is highly antigenic and the larvae 
are very susceptible to ADCC [26]. Plasma 
elimination half-life for the unchanged drug is 1-
1.5 h and 4-5 h for metabolites after a single 
dose, ruling out the effect of drug residue on the 
challenge parasites. 
           There was a significant difference 
between groups vaccinated before treatment 
(Infected-Vaccinated-Treated group, and the 
Vaccinated-Treated control group) and the group 
vaccinated after treatment (Infected-Treated-
Vaccinated group), using both the ANOVA and 
Kruskal Wallis test. However, no significant 
difference was found between the Infected-
Vaccinated-Treated group, and the Vaccinated-
Treated control group. This points to the fact 
that vaccination before or after treatment affects 
the worm burden. 
         The Vaccinated-Treated control group had 
the highest protection level of protection, 96.5%. 
A protection level of 60-70% has been reported 
for C57BL/6 mice [10]. The high protection 
level could be as a result of a different strain of 
mice, which is more resistant, and or to 
treatment with praziquantel after vaccination, 
which could have enhanced the immune 
protective mechanism. 
         Infected-Vaccinated-Treated mice had the 
second highest level of protection, 68.9% which 
is in the normal range of reported protection for 
mice [10]. The Infected-Treated-Vaccinated 
group had the lowest protection level of 41%.          
It is obvious that mice which were vaccinated 
before praziquantel treatment (Infected-
Vaccinated-Treated and Vaccinated-Treated 
Control groups) had higher resistance against 
challenge parasites as compared to mice that 
were treated with praziquantel before 
vaccination (Infected-Treated-Vaccinated 
group). The high anti-worm activity in Infected-
Vaccinated-Treated and Vaccinated-Treated 
Control groups could be attributed to the 
synergistic effects of praziquantel and the 
vaccine. The reason being that the effectiveness 
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of praziquantel against S. mansoni infections is 
increased in vaccinated mice [27]. This explains 
why synergistic effect was not substantial in 
Infected-Treated-Vaccinated group, which was 
treated before vaccination. This observation is 
consistent with other experimental findings that 
showed the enhanced efficacy of the drug in 
immune sensitised hosts [28, 29]. 
The protection levels in these three groups seem 
to correlate very well with the proliferative 
responses. The Vaccinated-Treated Control 
group had the best proliferative responses after 
vaccination, followed by Infected-Vaccinated-
Treated group and then the Infected-Treated-
Vaccinated group. This points to the 
involvement of cellular immunity in protection. 
Although the presence of antibodies seems 
essential for protection, there is no consistent 
association between antibody levels and level of 
protection. It seems that antibody specificity 
rather than quantity is more relevant to 
protective immunity. However, the level of 
antibody seems to correlate very well with the 
amount of antigen in the circulation. This was 
demonstrated by: the peak at week 6 and sharp 
drop at week 7 of the Infected-Treated-
Vaccinated group, corresponding to high 
antigenic load from dead worms, and its 
clearance, respectively; consistently high levels 
of IgG in Infected-Vaccinated-Treated group, 
which had high antigenic loads throughout the 
experiment; and the correlation of level of IgG 
at week 4 post-challenge for the three vaccinated 




Mesenteric lymph nodes that drain the 
duodenum, caecum, colon and ileum were 
enlarged in all the mice groups. It has been 
observed that large amounts of schistosome 
antigens are conveyed to the mesenteric lymph 
nodes and become sequestered in the medullary 
cords [30].  
         Peak hepatic granulomas were measured 
from mice in both the Infected-Treated-
Vaccinated and Infected-Vaccinated-Treated 
groups at week 9 weeks post-infection. This 
finding was in agreement with the established 
period of peak (acute) granulomas in mice. 
Granuloma peaks in size by 8-10 weeks after 
infection [31]. There was significant reduction 
(P<0.05) in hepatic granuloma size in Infected-
Vaccinated-Treated and Infected-Treated-
Vaccinated groups by week 16 post-infection. 
This was in accordance to other studies where 
hepatic granulomas begin to reduce in size and 
cellularity after about 10 weeks post-infection 
such that by 16 - 20 weeks post-infection, the 
granulomas are about half the size of acute 
granuloma [32]. This process is termed as 
immunomodulation. However, there was an 
unusual observation in mice from the Infected-
Treated-Vaccinated and Infected-Vaccinated-
Treated groups at week 17 post-infection. The 
hepatic granulomas from these mice showed 
significant (P<0.05) increase in size. At week 17 
post-infection, parasite antigens and soluble egg 
antigens were being released continuously into 
host circulation from the challenge parasites. 
Consequently, the subsequent cellular 
infiltration caused by increased cross-reactivity 
of antigens from challenge schistosomula and 
schistosome eggs, may have caused 'old 
granulomas' to appear larger. Interchanging 
treatment and vaccination did not seem to 
unduly affect granuloma progression. 
          The formation of granulomas around 
schistosome eggs in the liver and the intestine is 
the major cause of pathology in schistosome 
infections. The live miracidia within each egg 
secretes antigenic materials through 
ultrasmicroscopic pores in the shell [33]. These 
antigens, continually released for 2 to 4 weeks, 
induce host sensitisation and recruitment of 
macrophages, lymphocytes, giant cells, 
fibroblasts and numerous eosinophils to 
comprise the host granulomatous response [33]. 
Granulomas are thought to be host protective, as 
they wall-off toxic egg products, such as 
hepatotoxic antigen omega-1 [34], which would 
otherwise kill the host, (and consequently, the 
parasite too). In mice infected with S. mansoni, 
egg deposition begins about 4 to 5 weeks after 
infection with the first detectable granulomas 
present by about 6 weeks. The granulomas were 
large due to peak cellular responses in the host 
because of schistosomula surface antigens and 
worm tegumental antigens cross-reacting to egg 
antigens [21]. The presence of worms in the 
liver could be attributed to praziquantel 
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caused worms to be dislodged and then be swept 
via the portal system to the liver.  
 
Conclusion 
In conclusion, administering vaccine before 
praziquantel treatment gave better protective 
results as compared to administering vaccine 
after treatment. The best results were obtained 
when the vaccine was administered to naïve 
mice. There was a correlation between the 
protective levels and proliferative responses 
implicating cellular involvement in protection. 
Although the level of IgG seemed to correlate 
with antigenic load, there was no consistent 
association between antibody levels and the 
level of protection. Praziquantel seemed to 
influence protective immunity positively when 
administered after vaccination, but not before. It 
also seemed to have protective effect on mice 
treated before infection. Granuloma progression 
in Infected-Treated-Vaccinated and Infected-
Vaccinated-Treated groups was rather similar. It 
followed the normal process of increase in size 
followed by modulation, except that the 
challenge infection resulted into increase in size 
in modulating granulomas in both groups. 
This work shows that it is crucial to know the 
state of vaccination target group before and 
during administration of a vaccine, as varying 
results may be obtained depending on the status 
of the individual before vaccination. 
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